Glaukos Corp Stock
€99.50
Your prediction
Glaukos Corp Stock
Pros and Cons of Glaukos Corp in the next few years
Pros
Cons
Performance of Glaukos Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Glaukos Corp | -0.970% | 2.051% | 11.798% | 15.698% | 1.015% | 118.202% | 37.241% |
| Neogen Corp. | 3.580% | 6.534% | 2.095% | 86.435% | 39.447% | - | - |
| CONMED Corp. | -0.630% | 4.667% | -4.848% | -37.822% | -10.286% | -67.292% | -72.456% |
| Bio-Techne Corp. | -1.220% | 3.000% | 3.904% | 7.682% | -5.240% | -31.827% | - |
News
Director Sells GKOS 15,000 Shares for $1.9 Million
Marc Stapley, a director at Glaukos Corporation (NYSE:GKOS), executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on Jan. 22, 2026, following the exercise of
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.
Brown Capital
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by


